肿瘤基础与临床
腫瘤基礎與臨床
종류기출여림상
JOURNAL OF BASIC AND CLINICAL ONCOLOGY
2014年
2期
113-115
,共3页
晚期胰腺癌%吉西他滨%化疗
晚期胰腺癌%吉西他濱%化療
만기이선암%길서타빈%화료
advanced pancreatic cancer%gemcitabine%chemotherapy
目的:比较吉西他滨联合化疗与吉西他滨单药化疗治疗晚期胰腺癌的疗效。方法62例晚期胰腺癌患者分为2组:吉西他滨联合化疗组(35例,包括吉西他滨联合奥沙利铂、吉西他滨联合顺铂、吉西他滨联合氟尿嘧啶、吉西他滨联合替吉奥方案),吉西他滨单药化疗组(27例),比较2组化疗的临床疗效及毒副反应。结果2组总有效率及临床受益率比较差异无统计学意义(P >0.05);联合化疗组毒副反应较单药化疗组高(P <0.05)。结论吉西他滨联合化疗与其单药化疗治疗晚期胰腺癌的临床疗效以及临床受益相似,但前者的毒副反应发生率较高。
目的:比較吉西他濱聯閤化療與吉西他濱單藥化療治療晚期胰腺癌的療效。方法62例晚期胰腺癌患者分為2組:吉西他濱聯閤化療組(35例,包括吉西他濱聯閤奧沙利鉑、吉西他濱聯閤順鉑、吉西他濱聯閤氟尿嘧啶、吉西他濱聯閤替吉奧方案),吉西他濱單藥化療組(27例),比較2組化療的臨床療效及毒副反應。結果2組總有效率及臨床受益率比較差異無統計學意義(P >0.05);聯閤化療組毒副反應較單藥化療組高(P <0.05)。結論吉西他濱聯閤化療與其單藥化療治療晚期胰腺癌的臨床療效以及臨床受益相似,但前者的毒副反應髮生率較高。
목적:비교길서타빈연합화료여길서타빈단약화료치료만기이선암적료효。방법62례만기이선암환자분위2조:길서타빈연합화료조(35례,포괄길서타빈연합오사리박、길서타빈연합순박、길서타빈연합불뇨밀정、길서타빈연합체길오방안),길서타빈단약화료조(27례),비교2조화료적림상료효급독부반응。결과2조총유효솔급림상수익솔비교차이무통계학의의(P >0.05);연합화료조독부반응교단약화료조고(P <0.05)。결론길서타빈연합화료여기단약화료치료만기이선암적림상료효이급림상수익상사,단전자적독부반응발생솔교고。
Objective To compare the curative effect of gemcitabine combined chemotherapy with gemcitabine single-agent chemotherapy in the treatment of advanced pancreatic cancer. Methods Sixty-two cases of advanced pancreatic cancer were divided into two groups:35 cases of the gemcitabine combined chemotherapy group(a com-bination of gemcitabine and oxaliplatin,gemcitabine and cisplatin gemcitabine and fluorouracil or gemcitabine and S-1),27 cases of the gemcitabine single-agent chemotherapy group,the curative effect and toxicities of chemotherapy between the two groups were observed comparatively. Results There was no statistical difference in the total re-sponse rate and the clinical benefit rate between the two groups(P > 0. 05). The toxicity incidences of the gemcit-abine combined chemotherapy group were higher than those of the gemcitabine single-agent chemotherapy group. Conclusion The curative effect of gemcitabine combined chemotherapy is similar to gemcitabine single-agent chemotherapy in the treatment of advanced pancreatic cancer,but the former has the higher incidences of toxicities.